- Home
- ADUS vs NVCR Comparison
ADUS vs NVCR Comparison
Compare ADUS & NVCR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ADUS
- NVCR
- Stock Information
- Founded
- ADUS 1979
- NVCR 2000
- Country
- ADUS United States
- NVCR Switzerland
- Employees
- ADUS N/A
- NVCR N/A
- Industry
- ADUS Medical/Nursing Services
- NVCR Medical/Dental Instruments
- Sector
- ADUS Health Care
- NVCR Health Care
- Exchange
- ADUS Nasdaq
- NVCR Nasdaq
- Market Cap
- ADUS 2.2B
- NVCR 2.3B
- IPO Year
- ADUS 2009
- NVCR 2015
- Fundamental
- Price
- ADUS $109.23
- NVCR $22.09
- Analyst Decision
- ADUS Buy
- NVCR Buy
- Analyst Count
- ADUS 10
- NVCR 5
- Target Price
- ADUS $135.30
- NVCR $33.40
- AVG Volume (30 Days)
- ADUS 182.3K
- NVCR 741.8K
- Earning Date
- ADUS 02-24-2025
- NVCR 02-27-2025
- Dividend Yield
- ADUS N/A
- NVCR N/A
- EPS Growth
- ADUS 23.71
- NVCR N/A
- EPS
- ADUS 4.37
- NVCR N/A
- Revenue
- ADUS $1,133,806,000.00
- NVCR $577,738,000.00
- Revenue This Year
- ADUS $10.71
- NVCR $19.97
- Revenue Next Year
- ADUS $24.57
- NVCR $2.83
- P/E Ratio
- ADUS $25.02
- NVCR N/A
- Revenue Growth
- ADUS 10.15
- NVCR 14.63
- 52 Week Low
- ADUS $85.94
- NVCR $11.70
- 52 Week High
- ADUS $136.72
- NVCR $34.13
- Technical
- Relative Strength Index (RSI)
- ADUS 25.48
- NVCR 36.77
- Support Level
- ADUS $112.91
- NVCR $21.38
- Resistance Level
- ADUS $117.07
- NVCR $22.95
- Average True Range (ATR)
- ADUS 2.86
- NVCR 0.86
- MACD
- ADUS -0.98
- NVCR 0.01
- Stochastic Oscillator
- ADUS 5.95
- NVCR 34.25
About ADUS Addus HomeCare Corporation
Addus HomeCare Corp is engaged in the provision of in-home personal care services. It operates through the segments such as Personal care segment, which is a key revenue driver, provides non-medical assistance with activities of daily living, primarily to persons who are at risk of hospitalization or institutionalization, such as the elderly, chronically ill and disabled. The Hospice segment provides physical, emotional and spiritual care for people who are terminally ill and their families. Its Home health segment provides services that are primarily medical in nature to those individuals who may require assistance during an illness or after surgery.
About NVCR NovoCure Limited
NovoCure Ltd serves in the healthcare sector of the United States. Its business involves the development, manufacture and commercialization of Tumor Treating Fields (TTFields) devices, including Optune Gio and Optune Lua, for the treatment of solid tumor cancers. Its pipeline consists of Trident, Lunar-2, Panova-3, Metis and other products and technologies for the treatment of Glioblastoma, Non-smell cell lung cancer and Pancreatic cancer. Geographically, the company derives majority of its revenue from the United States and rest from Germany, Japan and other markets.